IRIS Accounts Production v24.2.0.383 10871140 director 1.1.23 31.12.23 31.12.23 false true false false false true false Ordinary £1 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh108711402022-12-31108711402023-12-31108711402023-01-012023-12-31108711402021-12-31108711402022-01-012022-12-31108711402022-12-3110871140ns15:EnglandWales2023-01-012023-12-3110871140ns14:PoundSterling2023-01-012023-12-3110871140ns10:Director12023-01-012023-12-3110871140ns10:PrivateLimitedCompanyLtd2023-01-012023-12-3110871140ns10:SmallEntities2023-01-012023-12-3110871140ns10:AuditExempt-NoAccountantsReport2023-01-012023-12-3110871140ns10:SmallCompaniesRegimeForDirectorsReport2023-01-012023-12-3110871140ns10:SmallCompaniesRegimeForAccounts2023-01-012023-12-3110871140ns10:FullAccounts2023-01-012023-12-311087114012023-01-012023-12-3110871140ns10:OrdinaryShareClass12023-01-012023-12-3110871140ns10:CompanySecretary12023-01-012023-12-3110871140ns10:RegisteredOffice2023-01-012023-12-3110871140ns5:CurrentFinancialInstruments2023-12-3110871140ns5:CurrentFinancialInstruments2022-12-3110871140ns5:Non-currentFinancialInstruments2023-12-3110871140ns5:Non-currentFinancialInstruments2022-12-3110871140ns5:ShareCapital2023-12-3110871140ns5:ShareCapital2022-12-3110871140ns5:RetainedEarningsAccumulatedLosses2023-12-3110871140ns5:RetainedEarningsAccumulatedLosses2022-12-3110871140ns5:IntangibleAssetsOtherThanGoodwill2023-01-012023-12-3110871140ns5:PatentsTrademarksLicencesConcessionsSimilar2023-01-012023-12-3110871140ns5:PatentsTrademarksLicencesConcessionsSimilar2022-12-3110871140ns5:PatentsTrademarksLicencesConcessionsSimilar2023-12-3110871140ns5:PatentsTrademarksLicencesConcessionsSimilar2022-12-3110871140ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-12-3110871140ns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-12-3110871140ns5:Non-currentFinancialInstruments2023-01-012023-12-3110871140ns10:OrdinaryShareClass12023-12-31
REGISTERED NUMBER: 10871140 (England and Wales)











Unaudited Financial Statements

for the Year Ended 31 December 2023

for

Bodybio Limited

Bodybio Limited (Registered number: 10871140)






Contents of the Financial Statements
for the Year Ended 31 December 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Bodybio Limited

Company Information
for the Year Ended 31 December 2023







DIRECTOR: B Berman





SECRETARY: B Berman





REGISTERED OFFICE: 1010 Cambourne Road
Suite 305
Cambourne
Cambridge
Cambridgeshire
CB23 6DW





REGISTERED NUMBER: 10871140 (England and Wales)





ACCOUNTANTS: Knights Lowe Chartered Accountants
Eldo House
Kempson Way
Suffolk Business Park
Bury St Edmunds
Suffolk
IP32 7AR

Bodybio Limited (Registered number: 10871140)

Balance Sheet
31 December 2023

2023 2022
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 6,237 7,462

CURRENT ASSETS
Stocks 158,546 171,753
Debtors 5 108,252 26,046
Cash at bank 12,474 56,306
279,272 254,105
CREDITORS
Amounts falling due within one year 6 329,306 276,676
NET CURRENT LIABILITIES (50,034 ) (22,571 )
TOTAL ASSETS LESS CURRENT LIABILITIES (43,797 ) (15,109 )

CREDITORS
Amounts falling due after more than one
year

7

452,961

355,125
NET LIABILITIES (496,758 ) (370,234 )

CAPITAL AND RESERVES
Called up share capital 8 1 1
Retained earnings (496,759 ) (370,235 )
SHAREHOLDERS' FUNDS (496,758 ) (370,234 )

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Bodybio Limited (Registered number: 10871140)

Balance Sheet - continued
31 December 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 16 September 2024 and were signed by:





B Berman - Director


Bodybio Limited (Registered number: 10871140)

Notes to the Financial Statements
for the Year Ended 31 December 2023

1. STATUTORY INFORMATION

Bodybio Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Turnover is recognised on accruals basis when goods are dispatched to customers.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents and licences are being amortised evenly over their estimated useful life of ten years.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Financial instruments
The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable, and loans from banks or other related parties.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Going concern
The financial statements have been prepared on the going concern basis which assumes that the company will continue in operational existence for the foreseeable future. Having assessed the projected results and cash flow of the company, it is expected that the company will start trading and produce profits and generate cash in the year ended 31 December 2024. The company retains the support of the company's parent company via an inter company loan and funding when required. It is expected this arrangement will continue for the foreseeable future. Whilst there is always considerable uncertainty in predicting cash flows more than a few months into the future, the directors are confident that the cash demands of the company will be satisfied, and it is therefore appropriate to prepare the financial statements on the going concern basis.

Bodybio Limited (Registered number: 10871140)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2023

2. ACCOUNTING POLICIES - continued

Impairment
At each reporting date, goodwill and other fixed assets, including tangible fixed assets and investments but excluding investment properties, are assessed to determine whether there is an indication that the carrying amount of an asset may be more than its recoverable amount and that the asset should be impaired. If there is an indication of possible impairment, the recoverable amount of an asset, which is the higher of its value in use and its net realisable value, is estimated and compared with its carrying amount. If the recoverable amount is lower, the carrying amount of the asset is written down to its estimated recoverable amount and an impairment loss is recognised in the income statement.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2022 - 1 ) .

4. INTANGIBLE FIXED ASSETS
Patents
and
licences
£   
COST
At 1 January 2023
and 31 December 2023 12,251
AMORTISATION
At 1 January 2023 4,789
Amortisation for year 1,225
At 31 December 2023 6,014
NET BOOK VALUE
At 31 December 2023 6,237
At 31 December 2022 7,462

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade debtors 65,791 26,046
Other debtors 42,461 -
108,252 26,046

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade creditors 254,486 200,207
Taxation and social security 41,236 48,746
Other creditors 33,584 27,723
329,306 276,676

Bodybio Limited (Registered number: 10871140)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2023

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
2023 2022
£    £   
Other creditors 452,961 355,125

Other creditors due after more than one year is made up of amounts owed to group companies.

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2023 2022
value: £    £   
1 Ordinary £1 £1 1 1

9. ULTIMATE CONTROLLING PARTY

The company's parent company is Bodybio Inc. A company registered in USA at 45 Reese Road , Millville, New Jersey 08332